Technology Platform
ASG's core R&D advantage is its own special dosage form technology platform, which integrates three niche technologies: drug particle control manufacturing process, special formula process development and new inhalation device development to develop a drug that can enter the lungs and quickly increase the body's Innovative medicines for absorption.
aPPC : Aero-Particles Process Control Technology
ASG’s competitive advantage is to utilize our particle control technology and formulation adjustment to precisely control particle size and fluidity. Using polymers as excipients, APIs can form the lowest density particles, making the drugs easy to fly and with good dispersion. It can quickly reach an effective concentration in the human body and greatly improve the bioavailability. In addition, it can be used in the simplest way to combine excipients to form a stable drug structure, reduce side effects, and thus improve patients' adherence. This proprietary process technology is patented.
The science of formulating process development
Our advantage in manufacturing process development technology lies in the adjustment of formulation development parameters and the combination of suitable carriers. Generally speaking, typical drugs that are administered through inhalation dosage forms have only 10 to 30% effective dosage. ASG employs an unique formulation development process, including but not limited to the standardization of important parameters such as carrier properties, mixing ratio, and packaging methods. After API is mixed alone or with an suitable carrier, we can combine the API and excipients to form a low-density particles that can increase dispersibility of drugs, and the effective lung deposition rate is expected to increase by more than 60%. Drugs can be delivered in the form of capsules, blister shells or multi-dose depots, using specially designed dry powder inhalers to greatly improve bioavailability.
Development of new special inhaler devices
ASG's new drug development uses the specially designed new DPI device, supported by analysis of particle size, aerodynamics, ergonomics, and manufacturing aesthetics, for different drugs to achieve the goals of optimal absorption and convenient use. The advantage of the drug & device integration is that it can reduce the dosage meanwhile increase the drug deposition rate and bioavailability in patients. Furthermore, in order to improve patients' medication adherence and convenience and to facilitate analysis of treatment effectiveness, ASG is also developing electronic sensors to be combined with the device design to detect relevant data through our own patented artificial intelligence (“AI”) technology under development. The technology is intended to detect measures, such as flow rate and effective drug usage rate, to analyze drug usage status and to improve the efficiency of future drug development.
Global patents
All technologies of the ASG drug development platform, including but not limited to aPPC technology, drug formulation process, inhaler devices and electronic sensor devices, have acquired or have applied for patents. For the drugs in development, two formulations have been submitted to the U.S.. As we continue to develop new drugs, we are actively pursuing a global patent protection strategy. In addition to the above-mentioned patent applications, ASG has also developed its proprietary analytical and information processing technology based on AI in order to accelerate and improve the results of upcoming clinical trials. In Taiwan, it has already obtained multiple patents such as " Inspiration system related symptom sensing system and apparatus", "Information procession device and its dry powder inhaler", and " Medical Document Analysis System".